University Hospitals Seidman Cancer Center

Seidman Cancer Center at UH Case Medical

Cleveland, OH

Sorting 8 by

Not currently accepting

Talisman

A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity
  • Bispecific Antibody
  • GPRC5D
  • Randomization
  • Phase 2

Accepting patients

Investigational Cord Blood Units

Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
  • Allogeneic Stem Cell Transplant
  • Cord Blood
  • Phase 2

Accepting patients

LMY-920

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)
  • CAR T Cell
  • BAFF
  • Phase 1

Accepting patients

IDP-023

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
  • Natural Killer Cells (Allogeneic)
  • Phase 1/2

Accepting patients

Treatment Experience of Patients

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia (AML) Using Remote Symptom Monitoring

Not yet accepting

UF-KURE-BCMA CAR-T Cells

A Phase 1 Single Arm, Open Label Study to Evaluate the Safety of UF-KURE-BCMA CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma
  • CAR T Cell
  • BCMA
  • Phase 1

Accepting patients

Cord Blood Units for Neutrophil Recovery

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
  • Cord Blood
  • Observational Trial

Not currently accepting

MajesTEC-4

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
  • Bispecific Antibody
  • BCMA
  • Phase 3